RU2016147122A - Применение серелаксина для снижения gdf-15 - Google Patents
Применение серелаксина для снижения gdf-15 Download PDFInfo
- Publication number
- RU2016147122A RU2016147122A RU2016147122A RU2016147122A RU2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A
- Authority
- RU
- Russia
- Prior art keywords
- serelaxin
- patient
- biological sample
- gdf
- administered
- Prior art date
Links
- DTLOVISJEFBXLX-REAFJZEQSA-N relexan 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N1)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DTLOVISJEFBXLX-REAFJZEQSA-N 0.000 title claims 16
- 229960002792 serelaxin Drugs 0.000 title claims 16
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title claims 8
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title claims 8
- 238000000034 method Methods 0.000 claims 16
- 239000012472 biological sample Substances 0.000 claims 11
- 210000002966 serum Anatomy 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010037368 Pulmonary congestion Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
Claims (28)
1. Способ селективного лечения пациента с застоем в легких, включающий:
оценку легочной нагрузки у пациента с застоем в легких; и
после этого введение пациенту терапевтически эффективного количества серелаксина.
2. Способ по п. 1, где указанная оценка включает оценку биологического образца от пациента на наличие или отсутствие GDF-15.
3. Способ по любому из предшествующих пунктов, где серелаксин вводят для поддержания концентрации в сыворотке у пациента от 1 нг/мл до 100 нг/мл.
4. Способ по любому из предшествующих пунктов, где серелаксин вводят для поддержания концентрации в сыворотке у пациента 10нг/мл.
5. Способ по любому из предшествующих пунктов, где серелаксин вводят подкожно со скоростью введения от 3 мкг/кг/сутки до 150 мкг/кг/сутки.
6. Способ по любому из предшествующих пунктов, где серелаксин вводят подкожно со скоростью введения 30 мкг/кг/сутки.
7. Способ по любому из предшествующих пунктов, где серелаксин вводят непрерывно в течение, по меньшей мере, 24 часов.
8. Способ селективного снижения легочной нагрузки у пациента, включающий:
получение биологического образца от пациента;
измерение количества GDF-15 в биологическом образце; и
после этого введение терапевтически эффективного количества серелаксина в ответ на повышенный уровень GDF-15.
9. Способ по п. 8, где серелаксин вводят для поддержания концентрации в сыворотке у пациента от 1 нг/мл до 100 нг/мл.
10. Способ по любому из пп. 8-9, где серелаксин вводят для поддержания концентрации в сыворотке у пациента 10нг/мл.
11. Способ по любому из пп. 8-10, где серелаксин вводят подкожно со скоростью введения от 3 мкг/кг/сутки до 150 мкг/кг/сутки.
12. Способ по любому из пп. 8-11, где серелаксин вводят подкожно со скоростью введения 30 мкг/кг/сутки.
13. Способ по любому из пп. 8-12, где серелаксин вводят непрерывно в течение, по меньшей мере, 24 часов.
14. Способ определения прогноза смертности пациента с сердечной недостаточностью, включающий:
получение первого биологического образца от пациента;
определение уровня GDF-15 в первом биологическом образце;
введение терапевтически эффективного количества серелаксина;
получение второго биологического образца от пациента после введения серелаксина;
определение уровня GDF-15 во втором биологическом образце;
сравнение уровня GDF-15 в первом биологическом образце со вторым биологическим образцом; и
предсказание возможности выживания.
15. Способ по п. 14, где второй биологический образец получают через 2, 14, 60 или 180 суток после введения серелаксина.
16. Способ по п. 14, где сниженный уровень GDF-15 во втором биологическом образце предсказывает повышенную вероятность выживания.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011744P | 2014-06-13 | 2014-06-13 | |
| US62/011,744 | 2014-06-13 | ||
| PCT/IB2015/054399 WO2015189790A1 (en) | 2014-06-13 | 2015-06-10 | Use of serelaxin to reduce gdf-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016147122A true RU2016147122A (ru) | 2018-07-16 |
| RU2016147122A3 RU2016147122A3 (ru) | 2019-01-28 |
Family
ID=53476944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016147122A RU2016147122A (ru) | 2014-06-13 | 2015-06-10 | Применение серелаксина для снижения gdf-15 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170100460A1 (ru) |
| EP (1) | EP3154559B1 (ru) |
| JP (1) | JP6820748B2 (ru) |
| KR (1) | KR20170018829A (ru) |
| CN (1) | CN106413740A (ru) |
| AU (2) | AU2015273097A1 (ru) |
| BR (1) | BR112016028833A2 (ru) |
| CA (1) | CA2952061A1 (ru) |
| MX (1) | MX2016016414A (ru) |
| RU (1) | RU2016147122A (ru) |
| WO (1) | WO2015189790A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| CN105934249A (zh) | 2013-11-21 | 2016-09-07 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
| EP3693004A1 (en) * | 2014-08-01 | 2020-08-12 | The Brigham and Women's Hospital, Inc. | An inhibitor of gdf-15 for use in treating fibrosis |
| EP3331550B1 (en) | 2015-08-04 | 2022-11-02 | Acceleron Pharma Inc. | Composition for treating myeloproliferative disorders |
| SI3628049T1 (sl) | 2017-05-04 | 2023-10-30 | Acceleron Pharma Inc. | Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba |
| US20220238229A1 (en) * | 2019-06-20 | 2022-07-28 | Sony Group Corporation | Information processing apparatus, information processing method, and program |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106018820B (zh) * | 2006-08-04 | 2018-04-27 | 汉诺威医学院 | 根据gdf-15评价心脏介入风险的工具与方法 |
| ES2379104T3 (es) * | 2007-05-24 | 2012-04-20 | F. Hoffmann-La Roche Ag | Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15 |
| AR071810A1 (es) * | 2008-05-16 | 2010-07-14 | Corthera Inc | Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. |
| CN103930440A (zh) * | 2011-07-01 | 2014-07-16 | 拜耳知识产权有限责任公司 | 松弛素融合多肽及其用途 |
-
2015
- 2015-06-10 AU AU2015273097A patent/AU2015273097A1/en not_active Abandoned
- 2015-06-10 US US15/316,952 patent/US20170100460A1/en not_active Abandoned
- 2015-06-10 KR KR1020167034407A patent/KR20170018829A/ko not_active Withdrawn
- 2015-06-10 BR BR112016028833A patent/BR112016028833A2/pt not_active Application Discontinuation
- 2015-06-10 RU RU2016147122A patent/RU2016147122A/ru not_active Application Discontinuation
- 2015-06-10 WO PCT/IB2015/054399 patent/WO2015189790A1/en not_active Ceased
- 2015-06-10 CA CA2952061A patent/CA2952061A1/en not_active Abandoned
- 2015-06-10 CN CN201580032028.6A patent/CN106413740A/zh not_active Withdrawn
- 2015-06-10 JP JP2016572697A patent/JP6820748B2/ja not_active Expired - Fee Related
- 2015-06-10 EP EP15730858.6A patent/EP3154559B1/en not_active Not-in-force
- 2015-06-10 MX MX2016016414A patent/MX2016016414A/es unknown
-
2018
- 2018-03-29 AU AU2018202289A patent/AU2018202289A1/en not_active Abandoned
- 2018-09-21 US US16/137,770 patent/US20190022189A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018202289A1 (en) | 2018-04-26 |
| MX2016016414A (es) | 2017-04-10 |
| KR20170018829A (ko) | 2017-02-20 |
| EP3154559A1 (en) | 2017-04-19 |
| AU2015273097A1 (en) | 2016-11-17 |
| US20170100460A1 (en) | 2017-04-13 |
| US20190022189A1 (en) | 2019-01-24 |
| CA2952061A1 (en) | 2015-12-17 |
| CN106413740A (zh) | 2017-02-15 |
| BR112016028833A2 (pt) | 2017-08-22 |
| JP2017519008A (ja) | 2017-07-13 |
| JP6820748B2 (ja) | 2021-01-27 |
| WO2015189790A1 (en) | 2015-12-17 |
| EP3154559B1 (en) | 2021-09-01 |
| RU2016147122A3 (ru) | 2019-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016147122A (ru) | Применение серелаксина для снижения gdf-15 | |
| Guo et al. | Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1–mediated neutrophilic acute lung inflammation | |
| Grodin et al. | Clinical implications of serum albumin levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF | |
| JP2017519008A5 (ru) | ||
| EA201892347A1 (ru) | Способ и устройство для предоставления фармакокинетической схемы дозирования лекарственных препаратов | |
| EA201390543A1 (ru) | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат | |
| McEwan et al. | Autocrine regulation of wound healing by ATP release and P2Y2 receptor activation | |
| Sarma et al. | Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease | |
| IL272949B2 (en) | Improved treatment of atopic dermatitis with tradipitant | |
| de Almeida Faro et al. | Left ventricular hypertrophy in children, adolescents and young adults with sickle cell anemia | |
| Bilen et al. | High-grade inflammation in renal failure patients, according to mean platelet volume, improves at the end of two years after transplantation | |
| Bonella et al. | C42 SEARCHIN'FOR A CURE: NEW ILD TREATMENTS: Serum Kl-6 Levels Correlate With Response To Pirfenidone In Idiopathic Pulmonary Fibrosis | |
| Sánchez et al. | Hemodynamic and inflammatory markers of sleep apnea-hypopnea syndrome and nocturnal hypoxemia: effects of treatment with nasal continuous positive airway pressure | |
| Perfetti et al. | Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome | |
| RU2015130730A (ru) | Способ прогнозирования чувствительности к химиотерапии у больных с лимфопролиферативными заболеваниями | |
| Yadav et al. | B47 ACUTE RESPIRATORY DISTRESS SYNDROME: Postoperative Acute Respiratory Distress Syndrome Is Associated With A Distinct Biomarker Profile: A Case Control Study | |
| Burrage et al. | A23 COPD AND CARDIOVASCULAR DISEASE: STRANGE BEDFELLOWS: Physical Activity And Cardiovascular Risk In People With Stable COPD | |
| Kendrick et al. | S78 Lymphopaenia and increased ace levels stratify sarcoidosis patients to underlying increase in IFN-γ+ lymphocyte and TNF-α+ monocytes respectively | |
| Uzaslan et al. | D44 COPD: TREATMENT FROM BRONCHODILATORS TO OTHER PHARMACOLOGICAL INTERVENTIONS: How Ageing Effects Hospitalization In Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease? | |
| Muthiah et al. | Left Ventricular Assist Devices in Patients with Hypertrophic Cardiomyopathy | |
| Tatis Marenco et al. | Microalbuminuria factor de riesgo de daño renal en pacientes diabéticos e hipertensos | |
| Torres et al. | PKP-008 Assessment of the effectiveness of monitoring vancomycin in patients undergoing haemodialysis | |
| Kawataki | OC02. 06: The effective fetal screening using the distance between the descending aorta and left atrial posterior wall in four chamber view for Total Anomalous Pulmonary Venous Return. | |
| Xie et al. | The Effects of Rosuvastatin on Cardiac Function and Serum MPO, MMP-9 in Patients with Chronic Heart Failure | |
| Peña et al. | Hair cortisol and acute phase proteins as stress markers in pigs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190610 |